Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03551769




Registration number
NCT03551769
Ethics application status
Date submitted
17/05/2018
Date registered
11/06/2018

Titles & IDs
Public title
Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production
Scientific title
A Phase I, Open-label, Fixed-order, Single-dose, 2-Part, Crossover Study to Evaluate the Pharmacokinetics of a Formulation of Tricaprilin (AC-SD-01) Including the Effect of Food on Ketone Body Production in Caucasians and Asians
Secondary ID [1] 0 0
AC-18-016_FE
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - tricaprilin
Other interventions - standard meal
Other interventions - high-fat meal
Other interventions - overnight fast

Experimental: Cohort 1, Period 1 - Study drug administered concurrently with a standard meal

Experimental: Cohort 1, Period 2 - Study drug administered 30 minutes after a standard meal

Experimental: Cohort 1, Period 3 - Study drug administered 30 minutes after a high-fat meal

Experimental: Cohort 1, Period 4 - Study drug administered after an overnight fast

Experimental: Cohort 2, Period 1 - Study drug administered 30 minutes after a standard meal (Asian)

Experimental: Cohort 2, Period 2 - Study drug administered after an overnight fast (Asian)


Treatment: Drugs: tricaprilin
Tricaprilin formulated as AC-SD-01

Other interventions: standard meal
standard meal

Other interventions: high-fat meal
high-fat meal

Other interventions: overnight fast
fasting for at least 9 hours
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Total ketones
Timepoint [1] 0 0
1 day
Primary outcome [2] 0 0
Total ketones
Timepoint [2] 0 0
1 day
Primary outcome [3] 0 0
Total ketones
Timepoint [3] 0 0
1 day
Primary outcome [4] 0 0
Total ketones
Timepoint [4] 0 0
1 day
Primary outcome [5] 0 0
Total ketones
Timepoint [5] 0 0
1 day
Primary outcome [6] 0 0
B-hydrodxybutyrate
Timepoint [6] 0 0
1 day
Primary outcome [7] 0 0
B-hydroxybutyrate
Timepoint [7] 0 0
1 day
Primary outcome [8] 0 0
B-hydroxybutyrate
Timepoint [8] 0 0
1 day
Primary outcome [9] 0 0
B-hydroxybutyrate
Timepoint [9] 0 0
1 day
Primary outcome [10] 0 0
B-hydroxybutyrate
Timepoint [10] 0 0
1 day
Primary outcome [11] 0 0
Acetoacetate
Timepoint [11] 0 0
1 day
Primary outcome [12] 0 0
Acetoacetate
Timepoint [12] 0 0
1 day
Primary outcome [13] 0 0
Acetoacetate
Timepoint [13] 0 0
1 day
Primary outcome [14] 0 0
Acetoacetate
Timepoint [14] 0 0
1 day
Primary outcome [15] 0 0
Acetoacetate
Timepoint [15] 0 0
1 day
Secondary outcome [1] 0 0
tricaprilin
Timepoint [1] 0 0
1 day
Secondary outcome [2] 0 0
tricaprilin
Timepoint [2] 0 0
1 day
Secondary outcome [3] 0 0
tricaprilin
Timepoint [3] 0 0
1 day
Secondary outcome [4] 0 0
tricaprilin
Timepoint [4] 0 0
1 day
Secondary outcome [5] 0 0
tricaprilin
Timepoint [5] 0 0
1 day
Secondary outcome [6] 0 0
tricaprilin
Timepoint [6] 0 0
1 day
Secondary outcome [7] 0 0
octanoic acid
Timepoint [7] 0 0
1 day
Secondary outcome [8] 0 0
octanoic acid
Timepoint [8] 0 0
1 day
Secondary outcome [9] 0 0
octanoic acid
Timepoint [9] 0 0
1 day
Secondary outcome [10] 0 0
octanoic acid
Timepoint [10] 0 0
1 day
Secondary outcome [11] 0 0
octanoic acid
Timepoint [11] 0 0
1 day
Secondary outcome [12] 0 0
octanoic acid
Timepoint [12] 0 0
1 day
Secondary outcome [13] 0 0
Computerized Cognitive Battery - Attention
Timepoint [13] 0 0
1 day
Secondary outcome [14] 0 0
Computerized Cognitive Battery - Episodic Memory
Timepoint [14] 0 0
1 day
Secondary outcome [15] 0 0
Computerized Cognitive Battery - Working Memory
Timepoint [15] 0 0
1 day
Secondary outcome [16] 0 0
Computerized Cognitive Battery - Psychomotor Function
Timepoint [16] 0 0
1 day

Eligibility
Key inclusion criteria
* Healthy adult male, ages 18 - 55
* Able to consume a regular diet and one high fat meal; no specific dietary requirements
* Cohort 2 (Asian subject population) restricted to being of Japanese or Chinese heritage
Minimum age
18 Years
Maximum age
55 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Presence of any illness or condition that, in the opinion of the investigator might confound the study results or poses risk to the subject
* Has been on a ketogenic diet as supported by review of a food diary
* Has positive Urine Drug Screen or alcohol results at Screening

Study design
Purpose of the study
Other
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/08/2018
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Cerecin
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT03551769